Introduction

Uses for Matulane

Hodgkin’s Disease

Used in various combination therapy regimens; comparative efficacy continually being evaluated.102103104

Used in combination with mechlorethamine, vincristine, and prednisone (known as the MOPP regimen) in an alternating schedule with the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) for treatment of Hodgkin’s disease.101102103104

Used in combination with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone (increased-dose BEACOPP regimen) for treatment of advanced Hodgkin’s disease.101104

Use in other combination regimens for treatment of advanced Hodgkin’s disease being investigated.104

Risks Associated with MAO Inhibition

Hematologic Effects

Leukopenia, anemia, and thrombocytopenia occur frequently.100 Discontinue therapy if leukocyte count is <4000/mm3 or platelet count is <100,000/mm3.100 Consider possibility of inadequate marrow reserve in patients with leukopenia, thrombocytopenia, or anemia.100 (See Dosage Modification for Toxicity and Contraindications for Continued Therapy in Pediatric Patients and also in Adults under Dosage and Administration.)

Major Toxicities

GI Effects

Discontinue therapy if stomatitis (e.g., small ulceration or persistent soreness around the mouth) or diarrhea (frequent bowel movements or watery stools) occurs.100 (See Dosage Modification for Toxicity and Contraindications for Continued Therapy in Pediatric Patients and also in Adults under Dosage and Administration.)

Pediatric Use

Hepatic Impairment

Possible increased incidence of toxicity.100 Consider initiating therapy with the patient hospitalized.100 (See Adequate Patient Evaluation and Monitoring and also see Major Toxicities under Cautions.)

Renal Impairment

Possible increased incidence of toxicity.100 Consider initiating therapy with the patient hospitalized.100 (See Adequate Patient Evaluation and Monitoring and also see Major Toxicities under Cautions.)

Advice to Patients

Importance of avoiding alcoholic beverages and tobacco during therapy.100

Importance of avoiding foods with known high tyramine content such as wine, yogurt, ripe cheese, and bananas.100

Importance of women informing clinician if they are or plan to become pregnant or plan to breast-feed; necessity for clinicians to advise women to avoid pregnancy during therapy and to advise pregnant women of risk to the fetus.100

Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs (e.g., antihistamines) and dietary or herbal supplements, as well as any concomitant illnesses.100

Importance of advising patients of other important precautionary information.100 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.